JP2019528242A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528242A5
JP2019528242A5 JP2018565888A JP2018565888A JP2019528242A5 JP 2019528242 A5 JP2019528242 A5 JP 2019528242A5 JP 2018565888 A JP2018565888 A JP 2018565888A JP 2018565888 A JP2018565888 A JP 2018565888A JP 2019528242 A5 JP2019528242 A5 JP 2019528242A5
Authority
JP
Japan
Prior art keywords
acid sequence
seq
amino acid
polypeptide
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018565888A
Other languages
English (en)
Japanese (ja)
Other versions
JP6959268B2 (ja
JP2019528242A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/038169 external-priority patent/WO2017219034A2/en
Publication of JP2019528242A publication Critical patent/JP2019528242A/ja
Publication of JP2019528242A5 publication Critical patent/JP2019528242A5/ja
Priority to JP2021165271A priority Critical patent/JP7273918B2/ja
Application granted granted Critical
Publication of JP6959268B2 publication Critical patent/JP6959268B2/ja
Priority to JP2023074627A priority patent/JP2023086970A/ja
Priority to JP2025166337A priority patent/JP2026010692A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018565888A 2016-06-17 2017-06-19 第ｘａ因子誘導体の調製 Active JP6959268B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021165271A JP7273918B2 (ja) 2016-06-17 2021-10-07 第ｘａ因子誘導体の調製
JP2023074627A JP2023086970A (ja) 2016-06-17 2023-04-28 第ｘａ因子誘導体の調製
JP2025166337A JP2026010692A (ja) 2016-06-17 2025-10-02 第ｘａ因子誘導体の調製

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17
US62/351,841 2016-06-17
PCT/US2017/038169 WO2017219034A2 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021165271A Division JP7273918B2 (ja) 2016-06-17 2021-10-07 第ｘａ因子誘導体の調製

Publications (3)

Publication Number Publication Date
JP2019528242A JP2019528242A (ja) 2019-10-10
JP2019528242A5 true JP2019528242A5 (https=) 2020-06-11
JP6959268B2 JP6959268B2 (ja) 2021-11-02

Family

ID=60663351

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018565888A Active JP6959268B2 (ja) 2016-06-17 2017-06-19 第ｘａ因子誘導体の調製
JP2021165271A Active JP7273918B2 (ja) 2016-06-17 2021-10-07 第ｘａ因子誘導体の調製
JP2023074627A Pending JP2023086970A (ja) 2016-06-17 2023-04-28 第ｘａ因子誘導体の調製
JP2025166337A Pending JP2026010692A (ja) 2016-06-17 2025-10-02 第ｘａ因子誘導体の調製

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021165271A Active JP7273918B2 (ja) 2016-06-17 2021-10-07 第ｘａ因子誘導体の調製
JP2023074627A Pending JP2023086970A (ja) 2016-06-17 2023-04-28 第ｘａ因子誘導体の調製
JP2025166337A Pending JP2026010692A (ja) 2016-06-17 2025-10-02 第ｘａ因子誘導体の調製

Country Status (21)

Country Link
US (4) US10604748B2 (https=)
EP (3) EP4588932A3 (https=)
JP (4) JP6959268B2 (https=)
KR (1) KR102373215B1 (https=)
CN (3) CN118271391A (https=)
AU (2) AU2017283720C1 (https=)
CL (2) CL2018003654A1 (https=)
CO (1) CO2019000120A2 (https=)
DK (1) DK3472314T3 (https=)
EA (1) EA037815B1 (https=)
ES (2) ES2875538T3 (https=)
HU (1) HUE054597T2 (https=)
IL (1) IL263591B2 (https=)
MX (1) MX2018015873A (https=)
PE (1) PE20190661A1 (https=)
PH (1) PH12018502614A1 (https=)
PL (1) PL3472314T3 (https=)
PT (1) PT3472314T (https=)
SG (1) SG11201810915QA (https=)
SI (1) SI3472314T1 (https=)
WO (1) WO2017219034A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3121271B1 (en) * 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
CA2898975C (en) * 2013-01-24 2021-06-15 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
PT3472314T (pt) * 2016-06-17 2021-06-18 Alexion Pharma Inc Preparação de derivados do fator xa
JP2021527435A (ja) 2018-06-19 2021-10-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤に対する解毒剤
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) * 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
JPH1066572A (ja) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd 高純度の大豆トリプシンインヒビターの製造方法
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
PE20070717A1 (es) 2005-11-08 2007-08-17 Millennium Pharm Inc Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
EP2915564B1 (en) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
MX2011004907A (es) 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
EP3121271B1 (en) * 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
JP6261093B2 (ja) * 2012-06-14 2018-01-17 ポートラ ファーマシューティカルズ， インコーポレイテッド 組み換え第Ｘａ因子誘導体の精製のための方法
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CA2898975C (en) * 2013-01-24 2021-06-15 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
EP3049434A1 (en) * 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP3750556A1 (en) * 2014-08-20 2020-12-16 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
PT3472314T (pt) * 2016-06-17 2021-06-18 Alexion Pharma Inc Preparação de derivados do fator xa

Similar Documents

Publication Publication Date Title
JP2019528242A5 (https=)
JP6593721B2 (ja) 高純度の組換えヒト血清アルブミンを単離、精製するクロマトグラフ法
JP2022028833A (ja) 抗菌療法
EP1268551B1 (en) A METHOD OF PRODUCING IgG
CN106474470B (zh) 一种抗il-17a抗体的组合物
JP2016504040A5 (https=)
CN105017412B (zh) 一种从牛血清中分离高纯度牛血清白蛋白的方法
EA027325B1 (ru) Составы этанерцепта, стабилизированные ксилитом
RU2014123990A (ru) Антитело к адреномедуллину (adm) или фрагмент анти-adm антитела, или анти-adm he-iq каркас для применения в терапии
JP2018515766A (ja) ポリペプチド混合物の高速液体クロマトグラフィー分析方法
CN104592293B (zh) 一种高含量磷脂酰乙醇胺的制备方法
CN103159829A (zh) 达托霉素的提取方法
JP2018507175A5 (https=)
CN105435221B (zh) 一种针对血管内皮生长因子的人源化抗体的药物组合物
CN101525382B (zh) 一种纯化普兰林肽的方法
JP6303379B2 (ja) 抗体の精製方法
CN102174100A (zh) 多肽cw7213纯化工艺方法
CN1242059C (zh) rDSPAα I 的产生方法
CN104936610A (zh) Glp-1类似物的纯化方法
CN106565827B (zh) 一种高度纯化糖肽类化合物的方法
CN106866789A (zh) 一种分离纯化达托霉素rs-8杂质的方法
CN115850383A (zh) 一种雷扎芬净纯化方法
JPWO2017154869A1 (ja) 変異型ヒトエリスロポエチンの製造方法
RU2004126196A (ru) Способ получения, выделения, очистки и стабилизации рекомбинантного гранулоцитарного колониестимулирующего фактора человека, пригодного для медицинского применения и иммунобиологическое средство на его основе
CN105541994A (zh) 一种血小板生成素或其变体或衍生物的纯化方法